1. |
Kido A, Miyake M, Tamura H, et al. Incidence of central serous chorioretinopathy (2011-2018): a nationwide population-based cohort study of Japan[J]. Br J Ophthalmol, 2022, 106(12): 1748-1753. DOI: 10.1136/bjophthalmol-2021-319403.
|
2. |
Daruich A, Matet A, Dirani A, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis[J]. Prog Retin Eye Res, 2015, 48: 82-118. DOI: 10.1016/j.preteyeres.2015.05.003.
|
3. |
Nicholson B, Noble J, Forooghian F, et al. Central serous chorioretinopathy: update on pathophysiology and treatment[J]. Surv Ophthalmol, 2013, 58(2): 103-126. DOI: 10.1016/j.survophthal.2012.07.004.
|
4. |
Loo RH, Scott IU, Flynn HW, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy[J]. Retina, 2002, 22(1): 19-24. DOI: 10.1097/00006982-200202000-00004.
|
5. |
Deng K, Gui Y, Cai Y, et al. Changes in the foveal outer nuclear layer of central serous chorioretinopathy patients over the disease course and their response to photodynamic therapy[J/OL]. Front Med (Lausanne), 2022, 14: 824239[2022-01-14]. https://europepmc.org/article/MED/35096914. DOI: 10.3389/fmed.2021.824239.
|
6. |
Zhao M, Zhang F, Chen Y, et al. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial[J]. JAMA Ophthalmol, 2015, 133(3): 333-340. DOI: 10.1001/jamaophthalmol.2014.5312.
|
7. |
Liang Z, Qu J, Huang L, et al. Comparison of the outcomes of photodynamic therapy for central serous chorioretinopathy with or without subfoveal fibrin[J]. Eye (Lond), 2021, 35(2): 418-424. DOI: 10.1038/s41433-020-0858-4.
|
8. |
Gao T, Qu J, Xiao J, et al. Photodynamic therapy for bullous retinal detachment: a single-center experience of case series with a 6-month follow-up study[J]. Graefe's Arch Clin Exp Ophthalmol, 2018, 256(8): 1429-1439. DOI: 10.1007/s00417-018-4015-8.
|
9. |
van Dijk EHC, Feenstra HMA, Bjerager J, et al. Comparative efficacy of treatments for chronic central serous chorioretinopathy: a systematic review with network meta-analyses[J]. Acta Ophthalmol, 2023, 101(2): 140-159. DOI: 10.1111/aos.15263.
|
10. |
Chen SN, Hwang JF, Tseng LF, et al. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage[J]. Ophthalmology, 2008, 115(12): 2229-2234. DOI: 10.1016/j.ophtha.2008.08.026.
|
11. |
Scholz P, Altay L, Fauser S. Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy[J]. Eye (Lond), 2016, 30(10): 1371-1377. DOI: 10.1038/eye.2016.142.
|
12. |
Roca JA, Wu L, Fromow-Guerra J, et al. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group[J]. Br J Ophthalmol, 2018, 102(12): 1696-1700. DOI: 10.1136/bjophthalmol-2017-311291.
|
13. |
Wood EH, Karth PA, Sanislo SR, et al. Nondamaging retinal laser therapy for treatment of central serous chorioretinopathy: what is the Evidence?[J]. Retina, 2017, 37(6): 1021-1033. DOI: 10.1097/IAE.0000000000001386.
|
14. |
van Dijk EHC, Fauser S, Breukink MB, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial[J]. Ophthalmology, 2018, 125(10): 1547-1555. DOI: 10.1016/j.ophtha.2018.04.021.
|
15. |
van Rijssen TJ, van Dijk EHC, Scholz P, et al. Focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser: PLACE trial report No. 3[J]. Am J Ophthalmol, 2019, 205: 1-10. DOI: 10.1016/j.ajo.2019.03.025.
|
16. |
Bae SH, Heo J, Kim C, et al. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial[J]. Ophthalmology, 2014, 121(2): 558-565. DOI: 10.1016/j.ophtha.2013.09.024.
|